Drugs / BMS-919373
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02153437 | Oct 2014 → Oct 2016 | atrial fibrillation | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Phase 1 | NCT02089061 | Mar → May 2014 | acute coronary syndrome | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02156076 | Jul 2014 → Jun 2016 | paroxysmal atrial fibrillation | Bristol-Myers Squibb | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-919373 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02153437 ↗ |
| Action | Inhibit | “IKur Inhibitor” NCT02089061 ↗ |
| Modality | Small molecule | — CHEMBL4094440 ↗ |
| Route | Oral | “BMS-919373 oral Solution/tablet single dose for one day” NCT02153437 ↗ |